Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pfizer Inc. (PFE) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, with AI‑powered tools to help interpret complex documents. As a large issuer in the pharmaceutical preparation manufacturing industry, Pfizer files a wide range of reports that are important for understanding its operations, capital structure and risk profile.
Investors can review Form 8‑K current reports that describe material events such as financial results, public offerings of notes, acquisitions and guidance updates. Recent 8‑K filings detail second‑ and third‑quarter 2025 financial results, full‑year 2025 and 2026 revenue and adjusted EPS guidance, a multi‑tranche public offering of senior notes with maturities extending to 2065, and the completed acquisition of Metsera, a company developing GLP‑1‑based obesity therapies.
Pfizer’s 8‑Ks also reference shelf registration statements and supplemental indentures governing its debt securities, as well as underwriting and pricing agreements with major investment banks. These filings help users track how Pfizer raises long‑term capital and manages its balance sheet. Other 8‑Ks furnish press releases under Regulation FD, including guidance updates that outline expected revenue contributions from COVID‑19 products and the impact of loss of exclusivity on certain medicines.
On Stock Titan, AI‑generated summaries highlight the key points of lengthy filings, explaining in plain language what new debt offerings, acquisitions, guidance changes or other events may mean for the company. Users can quickly identify which exhibits relate to indentures, legal opinions or merger agreements, and can follow how Pfizer’s financing activities and strategic transactions evolve over time.
In addition to 8‑Ks, this page links to Pfizer’s other core SEC reports, such as annual and quarterly filings, where available. Together, these documents provide a regulatory record of Pfizer’s financial performance, risk factors, capital markets activity and major corporate actions, with AI assistance to make the information more accessible.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported equity compensation activity and related tax withholding. On March 3, she received grants of Pfizer common stock totaling 21,719 shares in the form of restricted stock units, which are subject to vesting requirements, and 22,638 stock appreciation rights that will be settled in common shares on the fifth anniversary of the grant date.
On March 4, 826 shares of common stock were withheld to cover tax obligations when restricted stock units (and related dividend equivalents) vested. After these transactions, she directly held 32,934 Pfizer common shares.
Pfizer Inc. reported that Chairman and CEO Albert Bourla received a grant of 708,666 stock appreciation rights on March 3, 2026. These rights were acquired as a grant or award, not through open-market purchases.
According to the disclosure, the stock appreciation rights are subject to vesting conditions and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this transaction, Bourla held a total of 708,666 stock appreciation rights directly.
BOSHOFF CHRISTOFFEL reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. reported that President of R&D Christoffel Boshoff received a grant of 259,844 stock appreciation rights on March 3, 2026. These derivative awards carry no purchase price and are part of his equity-based compensation.
The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, aligning the executive’s potential reward with long-term company performance.
Pfizer Inc. reported that Chief Financial Officer and EVP David M. Denton received a grant of 216,537 Stock Appreciation Rights on March 3, 2026. These awards were acquired at a stated price of $0.00 per right, reflecting an equity-based compensation grant rather than an open-market purchase.
The footnote explains that the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. Following this grant, Denton’s reported direct derivative holdings in these rights total 216,537.
Pfizer Inc. Executive Vice President Douglas M. Lankler reported an acquisition of 194,883 stock appreciation rights on March 3, 2026. These derivative awards carry no exercise price and are scheduled to be settled in Pfizer common stock on the fifth anniversary of the grant date, subject to vesting conditions.
MALIK AAMIR reported acquisition or exercise transactions in this Form 4 filing.
Pfizer executive vice president Aamir Malik received a grant of 194,883 stock appreciation rights on March 3, 2026. These derivative awards were granted at no cost and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant, subject to vesting requirements.
Baum Andrew reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Andrew Baum reported an equity compensation grant in the form of 303,151 stock appreciation rights. These stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.
Pfizer Inc. Executive Vice President Lidia Fonseca reported receiving a grant of 82,284 stock appreciation rights on Pfizer common stock. These rights were acquired as a compensation award at a price of $0.0000 per right and are held as direct ownership.
According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, Fonseca held a total of 82,284 stock appreciation rights.
Pfizer Inc. Executive Vice President Michael McDermott received a grant of 151,576 Stock Appreciation Rights on March 3, 2026. These rights were acquired at a price of $0.00 per right as a form of equity-based compensation.
According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, McDermott directly holds 151,576 stock appreciation rights.
SAHNI PAYAL reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Payal Sahni received a grant of 108,268 stock appreciation rights. These derivative awards were granted at a price of $0.00 per right and are scheduled to be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, subject to vesting requirements.